Abstract 10575: The Effect of Empagliflozin on the Biomarker Growth Differentiation Factor 15 in Patients with Heart Failure and Reduced Ejection Fraction: A Post-Hoc Study of a Randomized, Double-Blind, and Placebo-Controlled Trial

Massar Omar,Jesper Ole Jensen,Caroline Kistorp,Kurt Højlund,Julie H. Larsen,Camilla Fuchs F Andersen,Lars Videbæk,Christian Tuxen,Mikael Kjær Poulsen,Finn Gustafsson,Lars Køber,Morten Schou,Jacob E. Møller

Abstract 10575: The Effect of Empagliflozin on the Biomarker Growth Differentiation Factor 15 in Patients with Heart Failure and Reduced Ejection Fraction: A Post-Hoc Study of a Randomized, Double-Blind, and Placebo-Controlled Trial

2021

Massar Omar
Jesper Ole Jensen
Caroline Kistorp
Kurt Højlund
Julie H. Larsen
Camilla Fuchs F Andersen
Lars Videbæk
Christian Tuxen
Mikael Kjær Poulsen
Finn Gustafsson
Lars Køber
Morten Schou
Jacob E. Møller

Introduction: Growth differentiation factor 15 (GDF-15) is considered as a biomarker of inflammatory and myocardial tissue injury. However, metformin increases plasma GDF-15, and may be responsible...

Keywords:

GDF15
Metformin
Cardiology
Placebo-controlled study
Biomarker (medicine)
Internal medicine
Ejection fraction
Heart failure
Empagliflozin
in patient
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations